Sales Management

Carl Lentz

Email: *********@********.***

Address: **** ******* **.

City: Waynesville

State: OH

Zip: 45068

Country: USA

Phone: 973-***-****

Skill Level: Senior

Salary Range: $99,000

Willing to Relocate

Primary Skills/Experience:

See Resume

Educational Background:

See Resume

Job History / Details:

CARL M. LENTZ

2206 Buckeye Ct

Waynesville, OH 45068

937-***-**** ***********@*****.***

VISIONARY TECHNOLOGY AND OPERATIONS LEADER

Aligning technology with business to create opportunities and value.

PhD, Synthetic Organic Chemistry / Driven by Desire for Continual Improvement

* Technology Direction * Leadership

* Driving Growth thru Innovation * GMP New Product Development

* Commercial Development * Operations and Business Management

* Process Improvement * Lean Manufacturing

* Efficiency Improvement * Capital Project Management

* CGMP and ISO Quality * Team Building

* Strategy Development and Implementation

Accomplished senior executive with proven leadership capabilities built on foundation of broad career experience spanning technology, operations, commercial development, and business management. Able to identify new product opportunities through building new technology platforms onto existing core technology capabilities, and successful in capturing strategic value from incremental innovation. Effectively communicates with all intermediaries, including customers, suppliers, multiple organizational levels, and other stakeholders. Strong technical background in organic, inorganic, polymer chemistry, nanotechnology and GMP quality systems Holder of 13 patents.

CAREER HIGHLIGHTS

* Commercialized new pharmaceutical intermediates business valued at $200M in revenues, and drove $40M in revenues per year by commercializing 3 major new agrochemical opportunities with 2 European agrochemical producers.

* COGS Reduction - As head of operations reduced cost of goods sold by 20% during 2-year period by focusing on all aspects of process control and implementing Lean manufacturing methodology.

* Increased sales revenues by 50% ($30M) during 4-year period and achieved 60%+ gross margins by changing focus at a cGMP site from neutraceuticals to contract manufacturing of highly potent bulk active drugs.

* Identified new epoxy butane chemistry opportunities for pharmaceutical market, which led to construction of a $10M pilot facility and resulted in $15M in additional sales at high margins.

* Developed and implemented company-wide Innovation Process that reduced speed to market for new products by 50% leading to double digit growth with improved profitability over last 3 years.

PROFESSIONAL EXPERIENCE

TEMPTIME CORPORATION, Morris Plains, NJ 2008 - 2012

World leader in time-temperature medical device indicators that protect patients by alerting user that a medical product has been exposed to damaging temperatures. Temptime`s mission is to contribute to improvement of public health by developing and supplying GMP quality indicators to monitor temperature sensitive biologics, pharmaceutical products and medical devices.

Chief Operating Officer and Senior Vice President

Senior member of Executive Team reporting to president responsible for: Manufacturing, New Product Development, Technical Service, Quality (GMP quality system registered with FDA as a medical device producer), and IT.

CARL M. LENTZ PAGE TWO

* Revenue and Operating Profit Growth - In 3 year period improved process control by over 100% while increasing operational productivity and global yield. These improvements resulted in on time delivery performance of 99.0% while increasing number of shipments by 50% over same period with no added resources. Reduced cost of non-conformance due to complaints by 70%.

* Strategic Change in Direction / GMP Quality Culture - Driving force behind strategic change for company, led effort to formulate and implement strategy to focus primarily on pharmaceutical and biopharmaceutical market. To effectively implement this strategy, improved innovation process, GMP quality system and new product development. The successful implement of the strategy and supporting elements resulted in double digit growth over 3 years with increasing gross margins and many successful quality audits from pharmaceutical customers.

* Innovation Leadership - Developed and implement comprehensive innovation process including required elements of new product development and project management to meet pharmaceutical quality standards and reduce speed to market.

* Technology Leadership - Led due diligence to purchase new indicator technology which was subsequently improved resulting in 3 new products protected with 2 new patent applications.

FERRO CORPORATION, Cleveland, OH 2001 - 2008

Leading producer of specialty materials that enhance performance of products in a variety of end markets (consumer electronics, telecommunications, pharmaceuticals, building and renovation, appliances, transportation, household furnishings, and industrial products).

Worldwide Director of Technology 2005 - 2008

Chief Technology Officer 2001 - 2005

Directed research, new product development, application development and technical service, and process engineering for Organic and Inorganic Specialties business groups. Managed $28M R&D budget and over saw 200 employees located in technical centers in North America, Europe, and Asia. Member of corporate leadership team comprising the top 25 executives in the company and responsible for Ferro technology leadership team focused on improving management processes that drove value creation by technology. Reported to Senior VP / GM of Operations.

* Drug Manufacturing and Delivery - Initiated and established a cGMP Pharmaceutical bulk manufacturing facility focused on contract manufacturing of highly potent materials and particle engineering of bulk drugs to improve drug delivery.

Hired team and led technical effort to innovate the use of supercritical fluid for particle engineering of bulk active drugs, which was implemented into the cGMP Pharmaceutical facility as a new business generating positive earnings.

* Revenue and Profit Growth - Drove 50% increase in sales revenues ($30M) during 4-year period and achieved 60%+ gross margins by leading team in changing business focus at the cGMP site from neutraceuticals to contract manufacture of highly potent bulk active drugs.

* New Product Development and Commercialization - Spearheaded new product development effort that included implementation of a rigorous, automated, and well-defined new product commercialization process.

Effort resulted in 5 new product areas that build off core technologies of the group with potential sales in excess of $100M; multiple patents have been filed over a 1.5-year period.

New process driven by licensed software and processes for ideation collection / screening, confidentiality and non-disclosure agreements, joint development agreements, IP, technology awareness, knowledge management, technology effectiveness metrics, partnerships, and safety.

On track to generate $10M in sales and high gross margin through driving development of a pigment ink system for digital tile decoration. Identified commercial opportunity for digital application (ink jet / toner printing) of materials that have traditionally been screen printed, and collaborated with European dinnerware producer to develop new toner technology for dinnerware application.

CARL M. LENTZ PAGE THREE

EASTMAN CHEMICAL COMPANY, Kingsport, TN 1978 - 2001

$7.5B, 11,000-employee Fortune 500 company manufacturing and marketing chemicals, fibers, and plastics worldwide.

Director of Operations 1998 - 2001

Directed all operational aspects of 750-employee site, including HR, finance, production, health / safety and environment, technology, and process engineering functions. Collaborated with senior business management to implement business strategies for products produced at the site; products were a combination of contract-manufactured (1 product exclusively for 1 customer) and multi-customer products, and part of the site produced products under CGMP quality system for pharmaceutical customers. Focused on fostering a culture of continual improvement and implementing processes centered on TQM, lean manufacturing, behavior-based safety, and TPM.

* COGS Reduction - Reduced cost of goods sold by 20% during 2-year period by focusing on all aspects of process control and implementing a TQM process combined with a Lean manufacturing methodology.

* Safety Improvement - Drove 50% improvement in safety measures (lost time injuries, OSHA recordable incidents, and first aid cases) by implementing behavioral based safety process plant-wide.

* Efficiency Improvement - Improved labor efficiency measures 15% through lean manufacturing techniques, TQM, and TPM processes.

* Safety and Regulatory Compliance - Achieved OSHA star rating for site and gained cGMP pre-product approval from FDA which enabled production of intermediate of key new drug for Eli Lilly.

Director of Technology and Commercial Development 1994 - 1998

Directed technology and commercial development initiatives, with emphasis on identifying new business opportunities and profitable commercialization of these opportunities into various plant sites worldwide, and the development, scale up, and piloting chemical process to produce contract chemicals for customers. Major part of product line for Eastman fine chemicals was based on contract manufacturing for the pharmaceutical and agrochemical markets. Managed $600M product portfolio of new product opportunities with technology budget of $22M. Oversaw 15 direct reports located in U.S., Europe, and Asia, and 55 technology reports located in U.S. and Europe.

* Commercial Development - Commercialized new pharmaceutical intermediates business valued at $200M in revenues and drove $40M in revenues per year by commercializing 3 major new agrochemical opportunities with 2 European agrochemical producers.

* Process Development and Improvement - Developed new manufacturing processes to continuously produce bleach activator for Tide, which generated $80M in new revenues and has continued to grow to more than $150M in sales.

* Cost Savings - Captured $20M+ in product scale-up cost savings by implementing and leveraging model reactor technology to replace costly pilot runs and unsuccessful startup batches.

* Customer Negotiations - Negotiated contract manufacturing deals that required customers to pay development and capital costs required for their product commercialization - an approach that has changed the dynamic in the industry and has given Eastman a competitive advantage.

EDUCATION / CERTIFICATIONS

* PhD, Synthetic Organic Chemistry, Johns Hopkins University, Baltimore, MD

* BS, Chemistry, James Madison University, Harrisonburg, PA

* Six Sigma Black Belt

* American Management Association Innovation Certification

* CGMP Quality Management Certification

* Eastman Chemical Business Management Curriculum Certification

* Baldridge Quality Assessor

* Performance Management Certification

* Strategic Marketing Certification

* Intellectual Property Management

AFFILIATIONS / AWARDS

* American Chemical Society

* Research and Technology Executive Council

* Board Member of the Color Pigments Manufacturing Association

* Materials Research Society

* Society of Organic Chemical Manufacturers

* Who`s Who 2011 Executive of the Year Pharmaceutical and Biopharmaceutical Section,

* Distinguished Alumni Award, James Madison University Alumni, 1997

Complete Listing of Publications and Patents Available Upon Request

Contact this candidate